265 related articles for article (PubMed ID: 34290717)
1. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
Ali YM; Ferrari M; Lynch NJ; Yaseen S; Dudler T; Gragerov S; Demopulos G; Heeney JL; Schwaeble WJ
Front Immunol; 2021; 12():714511. PubMed ID: 34290717
[TBL] [Abstract][Full Text] [Related]
2. Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein.
Beirag N; Varghese PM; Neto MM; Al Aiyan A; Khan HA; Qablan M; Shamji MH; Sim RB; Temperton N; Kishore U
Viruses; 2023 May; 15(6):. PubMed ID: 37376569
[TBL] [Abstract][Full Text] [Related]
3. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Rambaldi A; Gritti G; Micò MC; Frigeni M; Borleri G; Salvi A; Landi F; Pavoni C; Sonzogni A; Gianatti A; Binda F; Fagiuoli S; Di Marco F; Lorini L; Remuzzi G; Whitaker S; Demopulos G
Immunobiology; 2020 Nov; 225(6):152001. PubMed ID: 32943233
[TBL] [Abstract][Full Text] [Related]
4. Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoprotein.
Bally I; Drumont G; Rossi V; Guseva S; Botova M; Reiser JB; Thépaut M; Dergan Dylon S; Dumestre-Pérard C; Gaboriaud C; Fieschi F; Blackledge M; Poignard P; Thielens NM
Front Immunol; 2024; 15():1419165. PubMed ID: 38911852
[TBL] [Abstract][Full Text] [Related]
5. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs.
Gupta A; Gupta GS
Mol Cell Biochem; 2021 Aug; 476(8):2917-2942. PubMed ID: 33745077
[TBL] [Abstract][Full Text] [Related]
6. Complement Activation
Niederreiter J; Eck C; Ries T; Hartmann A; Märkl B; Büttner-Herold M; Amann K; Daniel C
Front Immunol; 2022; 13():835156. PubMed ID: 35237273
[TBL] [Abstract][Full Text] [Related]
7. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.
Charitos P; Heijnen IAFM; Egli A; Bassetti S; Trendelenburg M; Osthoff M
Front Immunol; 2021; 12():765330. PubMed ID: 34777382
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Lectin Pathway of Complement Activation Reduces Acute Respiratory Distress Syndrome Severity in a Mouse Model of SARS-CoV-2 Infection.
Ali YM; Carnell GW; Fumagalli S; Mercurio D; Seminara S; Lynch NJ; Khatri P; Arachchilage CH; Mascheroni L; Kaminski C; George CL; Stewart H; Yabuki M; Demopulos G; Heeney JL; Schwaeble W
J Infect Dis; 2024 Mar; 229(3):680-690. PubMed ID: 37878754
[TBL] [Abstract][Full Text] [Related]
9. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
10. Plasma Lectin Pathway Complement Proteins in Patients With COVID-19 and Renal Disease.
Medjeral-Thomas NR; Troldborg A; Hansen AG; Gisby J; Clarke CL; Prendecki M; McAdoo SP; Sandhu E; Lightstone L; Thomas DC; Willicombe M; Botto M; Peters JE; Pickering MC; Thiel S
Front Immunol; 2021; 12():671052. PubMed ID: 33995410
[TBL] [Abstract][Full Text] [Related]
11. Complement lectin pathway activation is associated with COVID-19 disease severity, independent of
Hurler L; Szilágyi Á; Mescia F; Bergamaschi L; Mező B; Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Csuka D; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Würzner R; ; Lyons PA; Toonen EJM; Prohászka Z
Front Immunol; 2023; 14():1162171. PubMed ID: 37051252
[TBL] [Abstract][Full Text] [Related]
12. Complement Activation in Kidneys of Patients With COVID-19.
Pfister F; Vonbrunn E; Ries T; Jäck HM; Überla K; Lochnit G; Sheriff A; Herrmann M; Büttner-Herold M; Amann K; Daniel C
Front Immunol; 2020; 11():594849. PubMed ID: 33584662
[TBL] [Abstract][Full Text] [Related]
13. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation.
Gao T; Zhu L; Liu H; Zhang X; Wang T; Fu Y; Li H; Dong Q; Hu Y; Zhang Z; Jin J; Liu Z; Yang W; Liu Y; Jin Y; Li K; Xiao Y; Liu J; Zhao H; Liu Y; Li P; Song J; Zhang L; Gao Y; Kang S; Chen S; Ma Q; Bian X; Chen W; Liu X; Mao Q; Cao C
Signal Transduct Target Ther; 2022 Sep; 7(1):318. PubMed ID: 36100602
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
Jarlhelt I; Nielsen SK; Jahn CXH; Hansen CB; Pérez-Alós L; Rosbjerg A; Bayarri-Olmos R; Skjoedt MO; Garred P
Front Immunol; 2021; 12():767981. PubMed ID: 34804055
[TBL] [Abstract][Full Text] [Related]
15. The Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus.
Troldborg A; Thiel S; Trendelenburg M; Friebus-Kardash J; Nehring J; Steffensen R; Hansen SWK; Laska MJ; Deleuran B; Jensenius JC; Voss A; Stengaard-Pedersen K
J Rheumatol; 2018 Aug; 45(8):1136-1144. PubMed ID: 29907670
[TBL] [Abstract][Full Text] [Related]
16. The Influence of the Lectin Pathway of Complement Activation on Infections of the Respiratory System.
Świerzko AS; Cedzyński M
Front Immunol; 2020; 11():585243. PubMed ID: 33193407
[TBL] [Abstract][Full Text] [Related]
17. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules.
Stravalaci M; Pagani I; Paraboschi EM; Pedotti M; Doni A; Scavello F; Mapelli SN; Sironi M; Perucchini C; Varani L; Matkovic M; Cavalli A; Cesana D; Gallina P; Pedemonte N; Capurro V; Clementi N; Mancini N; Invernizzi P; Bayarri-Olmos R; Garred P; Rappuoli R; Duga S; Bottazzi B; Uguccioni M; Asselta R; Vicenzi E; Mantovani A; Garlanda C
Nat Immunol; 2022 Feb; 23(2):275-286. PubMed ID: 35102342
[TBL] [Abstract][Full Text] [Related]
18. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.
Magro C; Mulvey JJ; Berlin D; Nuovo G; Salvatore S; Harp J; Baxter-Stoltzfus A; Laurence J
Transl Res; 2020 Jun; 220():1-13. PubMed ID: 32299776
[TBL] [Abstract][Full Text] [Related]
19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
20. MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides.
Talsma DT; Poppelaars F; Dam W; Meter-Arkema AH; Vivès RR; Gál P; Boons GJ; Chopra P; Naggi A; Seelen MA; Berger SP; Daha MR; Stegeman CA; van den Born J;
Front Immunol; 2020; 11():732. PubMed ID: 32425936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
